Al­lo­gene spot­lights their off-the-shelf CAR-T con­tender ‘501 with a snap­shot on CRs and no GVHD

Al­lo­gene ex­ecs are out to rev­o­lu­tion­ize a field they played a ma­jor role in pi­o­neer­ing. And they will ar­rive — vir­tu­al­ly — at AS­CO with some sol­id ev­i­dence that they are on the right track.

The drug in the spot­light to­day is AL­LO-501, which re­searchers are putting through their paces in a Phase I tri­al for re­lapsed/re­frac­to­ry non-Hodgkin lym­phoma, in com­bi­na­tion with their oth­er in-house drug AL­LO-647 to di­rec­tion lym­phode­ple­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER